Abstract
Contrast-induced nephropathy (CIN) is a common and morbid complication of percutaneous coronary intervention (PCI), occurring in up to 5% of patients. CIN after PCI not only increases the morbidity/mortality risk, but is also associated with a large potential impact on costs, particularly in elderly Medicare patients. Our objective was to estimate the short- and long-term economic impact of CIN in Medicare patients undergoing PCI.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
